Stem cell transplantation for chronic lymphocytic leukaemia

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Autologous stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL) initially suggested potential cures.
• Recent data indicate ASCT may only extend disease-free survival in CLL patients.
• Challenges with progenitor cell mobilization and post-transplant myelodysplasia persist with ASCT.

Purpose of the Study:

• To evaluate the long-term impact and curative potential of ASCT in chronic lymphocytic leukemia (CLL).
• To assess the efficacy and safety of allogeneic stem cell transplantation (allo-SCT) in CLL, including reduced intensity conditioning.
• To underscore the importance of ongoing clinical trials for both ASCT and allo-SCT in CLL management.

Main Methods:

• Review of early and recent studies on ASCT for CLL.
• Analysis of outcomes from conventional and reduced intensity allogeneic stem cell transplantation (allo-SCT) in CLL.
• Emphasis on the necessity of randomized clinical trials for definitive assessment.

Main Results:

• ASCT for CLL shows limited evidence of long-term cure, primarily prolonging disease-free survival.
• Conventional allo-SCT had high early mortality but demonstrated curative potential.
• Reduced intensity conditioning (RIC) allo-SCT has lowered early mortality, but long-term cure rates are yet to be determined.

Conclusions:

• ASCT's role in curing CLL remains uncertain, necessitating further investigation via clinical trials.
• Reduced intensity allo-SCT offers a safer approach for CLL treatment, but its curative capacity requires validation in trials.
• Understanding CLL heterogeneity and prognostic factors is crucial for personalized treatment decisions balancing risks and benefits.